BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 18379354)

  • 21. Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer.
    Grimminger PP; Schneider PM; Metzger R; Vallböhmer D; Danenberg KD; Danenberg PV; Hölscher AH; Brabender J
    Clin Lung Cancer; 2010 Mar; 11(2):114-9. PubMed ID: 20199977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome and late recurrence in patients with completely resected stage IA non-small cell lung cancer.
    Maeda R; Yoshida J; Ishii G; Aokage K; Hishida T; Nishimura M; Nishiwaki Y; Nagai K
    J Thorac Oncol; 2010 Aug; 5(8):1246-50. PubMed ID: 20559152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
    Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
    Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of exhaled microsatellite alterations at 3p in NSCLC patients.
    Carpagnano GE; Spanevello A; Carpagnano F; Palladino GP; Prato R; Martinelli D; Digioia G; Foschino-Barbaro MP
    Lung Cancer; 2009 Jun; 64(3):334-40. PubMed ID: 18995925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular diagnosis and prognostic significance of lymph node micrometastasis in patients with histologically node-negative non-small cell lung cancer.
    Dai CH; Li J; Yu LC; Li XQ; Shi SB; Wu JR
    Tumour Biol; 2013 Apr; 34(2):1245-53. PubMed ID: 23355336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer.
    Navarro A; Diaz T; Gallardo E; Viñolas N; Marrades RM; Gel B; Campayo M; Quera A; Bandres E; Garcia-Foncillas J; Ramirez J; Monzo M
    J Surg Oncol; 2011 Apr; 103(5):411-5. PubMed ID: 21400525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China.
    Li Z; Yu Y; Lu J; Luo Q; Wu C; Liao M; Zheng Y; Ai X; Gu L; Lu S
    J Thorac Oncol; 2009 Jun; 4(6):702-9. PubMed ID: 19404215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent down-regulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases.
    Warnecke-Eberz U; Bollschweiler E; Drebber U; Pohl A; Baldus SE; Hoelscher AH; Metzger R
    Oncol Rep; 2008 Sep; 20(3):619-24. PubMed ID: 18695914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical value of lymphatic micrometastases in patients with non-small cell lung cancer.
    Verhagen AF; Bulten J; Shirango H; Thunnissen FB; van der Drift MA; van der Bruggen W; Tjan-Heijnen VC; van Swieten HA
    J Thorac Oncol; 2010 Aug; 5(8):1201-5. PubMed ID: 20588201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of death, local recurrence, and distant metastasis in completely resected pathological stage-I non-small-cell lung cancer.
    Hung JJ; Jeng WJ; Hsu WH; Chou TY; Huang BS; Wu YC
    J Thorac Oncol; 2012 Jul; 7(7):1115-23. PubMed ID: 22592210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
    Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
    Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
    Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
    J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between p53 mutation and clinicopathological features of non-small cell lung cancer.
    Guang SG; Ogura T; Sekine I; Yokozaki M; Esumi H; Kodama T; Nagai K
    Jpn J Clin Oncol; 1997 Aug; 27(4):211-5. PubMed ID: 9379505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.
    He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B
    Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pragmatic approach to the diagnosis of nodal micrometastases in early stage non-small cell lung cancer.
    Herpel E; Muley T; Schneider T; Palm E; Kieslich de Hol D; Warth A; Meister M; Storz K; Schnabel PA; Schirmacher P; Dienemann H; Hoffmann H
    J Thorac Oncol; 2010 Aug; 5(8):1206-12. PubMed ID: 20581709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer.
    Varlotto JM; Recht A; Nikolov M; Flickinger JC; Decamp MM
    Cancer; 2009 Feb; 115(4):851-8. PubMed ID: 19140203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
    Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
    Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunocytochemical detection of occult tumor cells in the bone marrow: prognostic impact on early stages of lung cancer.
    Nosotti M; Tosi D; Palleschi A; Rosso L; Mendogni P; Santambrogio L
    Eur Surg Res; 2008; 41(3):267-71. PubMed ID: 18594145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.